TD Asset Management Inc Takes Position in Glaukos Corporation $GKOS

TD Asset Management Inc bought a new position in shares of Glaukos Corporation (NYSE:GKOS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,184 shares of the medical instruments supplier’s stock, valued at approximately $1,157,000.

A number of other institutional investors also recently bought and sold shares of the business. UMB Bank n.a. boosted its holdings in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the last quarter. REAP Financial Group LLC acquired a new position in Glaukos during the third quarter valued at $40,000. AlphaQuest LLC boosted its holdings in Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares during the last quarter. SBI Securities Co. Ltd. grew its position in Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 362 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $112.10 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23. The firm has a market capitalization of $6.51 billion, a PE ratio of -34.39 and a beta of 0.70. The business’s 50 day moving average price is $116.00 and its 200-day moving average price is $100.74.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.40) EPS. As a group, equities research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director directly owned 34,905 shares in the company, valued at $3,744,259.35. The trade was a 12.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Marc Stapley sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director directly owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This represents a 28.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 325,000 shares of company stock worth $37,739,259. 5.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have commented on GKOS. The Goldman Sachs Group restated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Piper Sandler reissued an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. Stifel Nicolaus upped their price target on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. Finally, William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $133.69.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.